| Revenue growth | 41% YoY in FY26. |
|---|---|
| Margins | EBITDA margin 20.3%; PAT margin 14%; target 20-22% EBITDA for FY27. |
| Order book | 718+ clients; 98% retention rate; new orders for Quick Snap format. |
| Demand visibility | Strong visibility in nutraceuticals driving facility expansion. |
| Management confidence | High; confident in maintaining 14% PAT margins. |
Growth
FY26 Revenue up 41% to ₹146cr; EBITDA up 32% to ₹29.9cr; PAT grew to ₹20.5cr (14% margin).
Outlook
Guidance of 25-30% minimum growth for FY27; long-term target of ₹500cr revenue by FY29.
Risks
Raw material price volatility in solvents/packaging and potential lag in passing costs to customers.
Earnings Call filed with NSE, NSE: INFLUX. Summary written with AI assistance from the document.
Influx Healthtech Ltd: key numbers
- Share price
- ₹274.30
- Market cap
- ₹635.0 Cr
- Revenue (annual)
- ₹146.8 Cr
- Net profit (annual)
- ₹20.54 Cr
- P/E (TTM)
- 30.9×Sector 47.3×
- Promoter holding
- 73.53%
- FII holding
- 0.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Influx Healthtech Ltd
All →Influx Healthtech Legal & Regulatory
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
- Value
- ₹0.02 Cr
Influx Healthtech Annual General Meeting
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech Other Announcement
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.
Influx Healthtech Annual General Meeting
Influx Healthtech Ltd. has announced its 6th Annual General Meeting scheduled for September 18, 2026, and submitted its Annual Report for FY 2025-2026.
Influx Healthtech Board Meeting Outcome
The Board approved the Directors' Report for FY26 and fixed the 6th AGM for September 18, 2026. They also appointed a scrutinizer for the upcoming meeting.
Influx Healthtech Capacity Expansion: ₹10 Cr Investment
Influx Healthtech reallocated ₹10 Crore to expand its CDMO facility to 75,000 sq. ft. The expansion targets a 2.5x capacity increase by August 2026.
- Value
- ₹10.00 Cr
- Execution
- Expected to become operational by August 2026